Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Finished Goods: 2021-2024

Historic Finished Goods for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Dec 2024 value amounting to $3.3 million.

  • Mirum Pharmaceuticals' Finished Goods fell 37.37% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 37.37%. This contributed to the annual value of $3.3 million for FY2024, which is 65.22% down from last year.
  • According to the latest figures from FY2024, Mirum Pharmaceuticals' Finished Goods is $3.3 million, which was down 65.22% from $9.4 million recorded in FY2023.
  • Mirum Pharmaceuticals' Finished Goods' 5-year high stood at $9.4 million during FY2023, with a 5-year trough of $87,000 in FY2021.
  • In the last 3 years, Mirum Pharmaceuticals' Finished Goods had a median value of $3.3 million in 2024 and averaged $4.3 million.
  • In the last 5 years, Mirum Pharmaceuticals' Finished Goods soared by 4,311.68% in 2023 and then tumbled by 65.22% in 2024.
  • Over the past 4 years, Mirum Pharmaceuticals' Finished Goods (Yearly) stood at $87,000 in 2021, then spiked by 145.98% to $214,000 in 2022, then skyrocketed by 4,311.68% to $9.4 million in 2023, then crashed by 65.22% to $3.3 million in 2024.